ImmunityBio, Inc. (IBRX) FY2025 10-K Annual Report
ImmunityBio, Inc. (IBRX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 23, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
ImmunityBio, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Development and commercialization of biologic drugs, with focus on regulatory approvals and post-marketing requirements
- • New emphasis on commercialization efforts for approved product ANKTIVA and building sales, marketing, and distribution capabilities
Management Discussion & Analysis
- • Revenue started from ANKTIVA sales since May 2024; no dollar amounts or YoY change disclosed
- • Operating expenses expected to increase substantially due to commercialization and R&D expansion; no margin % figures provided
Risk Factors
- • Regulatory risk from potential NCCN guideline decision on BCG-unresponsive NMIBC papillary-only disease expansion expected Q1/Q2 2026
- • Geopolitical exposure via dependency on 33 countries with ANKTIVA approval including US, UK, EU, Saudi Arabia, and MENA launches
ImmunityBio, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$113M
▲ +668.3% YoY
Net Income
-$351M
▲ +15.0% YoY
Operating Margin
-226.0%
▲ +210823bp YoY
Net Margin
-310.2%
▲ +249459bp YoY
ROE
70.2%
▼ -1434bp YoY
Total Assets
$502M
▲ +31.1% YoY
EPS (Diluted)
$-0.38
▲ +38.7% YoY
Operating Cash Flow
-$305M
▲ +22.1% YoY
Source: XBRL data from ImmunityBio, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on ImmunityBio, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.